ARM
Arm today announced the appointment of new Board members Karen Dykstra, former Chief Financial and Administrative Officer of AOL and Jeff Sine, Co-Founder and Partner of Raine Group, effective immediately. These highly qualified leaders bring a diverse range of expertise to Arm as the company prepares for a potential public listing.
Arm Chief Executive Officer (CEO) Rene Haas said: “I extend a warm welcome to Karen and Jeff, both exceptional business leaders who will bring a depth and breadth of experience to the Arm Board.”
Arm also today announced the appointment of Jason Child as Chief Financial Officer (CFO). Child has more than 30 years of experience in leadership at high growth companies and scaling global finance functions. Child will join Arm on November 2, 2022 and lead the company’s global finance and IT organizations, reporting to Haas.
Haas added, “Jason is an experienced leader in global finance and technology. His extensive experience in financial management at public companies and IPO execution will be invaluable in preparation for a potential public listing. I look forward to working with him as part of the Arm leadership team as we continue to define the future of computing, built on Arm.”
Child will replace current CFO Inder Singh who will remain at Arm in an advisory role and assist in the transition through November before moving to a new opportunity.
Haas said, “I’d like to thank Inder for his contributions and leadership over these past few years. He has helped the company navigate many changes since joining in 2019, including building a strong organization with upgraded systems and processes in the finance, IT and cybersecurity teams. We wish him all the best moving forward.”
Child most recently served as senior vice president and CFO at Splunk from 2019. Prior to Splunk, Child held multiple CFO positions including at Groupon, which he helped to take public in 2011 and as CFO at Amazon International.
“Since its founding, Arm has had an incredible history of innovation and leadership in the semi-conductor industry,” said Child. “Arm is a world-class, category leader and I am thrilled to join as CFO during this exciting time for the company.”
About Karen Dykstra
Ms. Dykstra previously served as Chief Financial and Administrative Officer of AOL, a web portal and online service provider. Prior to AOL, she was a Partner at Plainfield Asset Management, and served as Chief Operating Officer and Chief Financial Officer of Plainfield Direct, Plainfield’s business development company. She previously spent over 25 years with Automatic Data Processing (ADP), a provider of human capital management solutions to employers, serving most recently as Chief Financial Officer. Ms. Dykstra is currently a director on the boards of VMware and Gartner, and has also served on the boards of Boston Properties, Crane and AOL.
About Jeff Sine
Mr. Sine is the Co-Founder and Partner of The Raine Group, a global merchant bank focused on technology, media and communications. Prior to founding Raine, he served as Vice Chairman and Global Head of Technology, Media & Telecom Investment Banking at UBS Investment Bank, was a Managing Director at Morgan Stanley and was an attorney at Sullivan & Cromwell in New York and London. Mr. Sine currently serves on the boards of many Raine portfolio companies and subsidiaries. He also serves on the boards of National Public Radio (NPR) (Vice-Chair), ITHAKA, Educational Testing Service (ETS) (Chair), American University and The Manhattan Theatre Club.
About Jason Child
Jason Child’s career spans 30 years across all aspects of global finance and strategy, accounting, capital markets/treasury, IPO execution and investor relations. He has extensive experience in scaling disruptive technologies within enterprise software/SaaS, e-commerce, local commerce, consumer hardware/IOT, and online residential real estate. He most recently served as senior vice-president and CFO at Splunk, a technology company specializing in application management, security and compliance, as well as business and web analytics. Before his executive leadership roles, Jason spent more than 11 years leading various global finance teams at Amazon, and served as CFO of Amazon International. Jason has served as a member of the board of directors of Coupang, Inc., an e-commerce company, since April 2022. He holds B.A. from the Foster School of Business at the University of Washington, where he currently serves on the Global Advisory Board.
About Arm
Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 230 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom